Browsing Tag
lonvoguran ziclumeran
2 posts
Intellia’s $400m OrbiMed facility gains relevance as lonvo-z wins FDA Priority Review
Intellia secured an OrbiMed facility of up to $400 million on September 4 and drew $75 million upfront. Four days later, the FDA accepted lonvo-z for Priority Review with a March 10, 2027 decision date, bringing the next $75 million regulatory tranche into sharper focus.
Why hereditary angioedema could become Intellia Therapeutics’ biggest CRISPR validation test
Find out how Intellia’s lonvo-z Phase 3 data could reshape HAE treatment and investor sentiment around in vivo CRISPR.